JCC:肠内营养和类固醇诱导治疗的克罗恩病患儿粘膜愈合的效果分析

2019-08-03 不详 MedSci原创

单一肠内营养[EEN]与皮质类固醇[CS]一样有效,可诱导克罗恩病[CD]缓解,但不会产生副作用。EEN似乎比类固醇更有效诱导粘膜愈合,但潜在的机制还不清楚。本项研究的目的是研究比较EEN与CS在CD患儿中的抗炎作用,并评估其与类固醇相比对肠道微生物群的调节作用。

目标
单一肠内营养[EEN]与皮质类固醇[CS]一样有效,可诱导克罗恩病[CD]缓解,但不会产生副作用。EEN似乎比类固醇更有效诱导粘膜愈合,但潜在的机制还不清楚。本项研究的目的是研究比较EEN与CS在CD患儿中的抗炎作用,并评估其与类固醇相比对肠道微生物群的调节作用。

方法
研究人员收集了19例年龄为6至17岁的新发活动性CD(Harvey-Bradshaw指数[HBI]> 5)的患者,其中纳入CS6例,EEN13例。使用临床参数HBI,内窥镜检查结果(克罗恩病内窥镜严重程度指数[CDEIS]评分)和粪便微生物群组成分析,在第0周和第8周对患者进行效果评估。

结果
在第8周时,13/13例EEN患者和5/6例类固醇患者临床缓解[HBI <5]; 与类固醇组相比,EEN [89%]的粘膜愈合率显着更高(CS:17%)。各组之间在生物学标记方面没有显着差异,但肠道微生物群特征在EEN诱导的缓解后转变为较高比例的Ruminococcus细菌。

结论
类固醇和EEN均诱导临床缓解。然而,具有EEN诱导的缓解的患者显示出更高的粘膜愈合速率,并且这与这些儿童中不同的肠道微生物群组成变化相关。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1691039, encodeId=da94169103980, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jan 12 15:02:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910993, encodeId=e72e1910993a9, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Sep 13 07:02:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313431, encodeId=16e6131343142, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Aug 04 15:02:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046881, encodeId=5a351046881fa, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Aug 03 03:02:00 CST 2019, time=2019-08-03, status=1, ipAttribution=)]
    2020-01-12 guoyibin
  2. [GetPortalCommentsPageByObjectIdResponse(id=1691039, encodeId=da94169103980, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jan 12 15:02:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910993, encodeId=e72e1910993a9, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Sep 13 07:02:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313431, encodeId=16e6131343142, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Aug 04 15:02:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046881, encodeId=5a351046881fa, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Aug 03 03:02:00 CST 2019, time=2019-08-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1691039, encodeId=da94169103980, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jan 12 15:02:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910993, encodeId=e72e1910993a9, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Sep 13 07:02:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313431, encodeId=16e6131343142, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Aug 04 15:02:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046881, encodeId=5a351046881fa, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Aug 03 03:02:00 CST 2019, time=2019-08-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1691039, encodeId=da94169103980, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Sun Jan 12 15:02:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910993, encodeId=e72e1910993a9, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Sep 13 07:02:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313431, encodeId=16e6131343142, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Aug 04 15:02:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046881, encodeId=5a351046881fa, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Aug 03 03:02:00 CST 2019, time=2019-08-03, status=1, ipAttribution=)]
    2019-08-03 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

相关资讯

Gastroenterology Report: MR可以评估英夫利昔单抗对肛周瘘管克罗恩病的治疗效果

关于抗肿瘤坏死因子治疗的肛周瘘管克罗恩病(PFCD)的影像学文献报道很少。在本项研究中评估了英夫利昔单抗(IFX)对PFCD的有效性,并根据临床和影像学表现评估探索了“深度缓解”的预测因子。

Gastroenterology:克罗恩病患儿排除饮食加部分肠内营养在诱导缓解中的疗效

目前,指南建议对患有轻度至中度克罗恩病(CD)的儿童进行单一肠内营养(EEN)的治疗方案,但实施具有挑战性。本项研究比较了EEN与CD排除饮食(CDED),即正常饮食加上部分肠内营养(PEN)治疗,在诱导缓解患儿肠道炎症中的效果。

Dig Dis Sci: 英夫利昔单抗治疗原发性无应答的克罗恩病患者的疗效

肿瘤坏死因子拮抗剂(TNF)对治疗中度-重度克罗恩病(CD)效果很好。但是大约三分之一的患者对TNFs有原发性无应答。目前还没有研究专门评估静脉注射TNF对原发性无应答的临床和内镜治疗效果。因此,本项研究旨在探究原发性无应答的克罗恩病患者再次接受英夫利西单抗治疗的效果。

Dig Dis Sci: 术后早期抗TNF治疗不会增加克罗恩病手术后的并发症

术后抗TNF治疗对克罗恩病手术后感染并发症的影响仍存在争议。术后2-4周使用抗TNF治疗似乎是安全的,但2周内使用安全性尚不清楚。因此,本项研究旨在评估克罗恩病患者腹部手术后2周内开始抗TNF治疗的效果。

Dig Liver Dis: 荟萃分析:抗TNFα药物是预防术后克罗恩病的更佳选择

尽管克罗恩病(CD)的术后复发率(POR)很高,但其预防达策略还未达成共识。本项研究的目的是比较生物疗法和常规疗法在预防CD的POR方面的功效。

Dig Liver Dis: ustekinumab在伴有银屑病或银屑病关节炎的炎症性肠病患者中的实际效果

关于ustekinumab在治疗伴有银屑病或银屑病关节炎的炎性肠病(IBD)患者中的有效性的数据很少。本项研究旨在探究患有银屑病或银屑病关节炎的炎性肠病(IBD)患者接受皮下ustekinumab注射治疗的效果。